公开(公告)号：US20200087392A1

公开(公告)日：2020-03-19

申请号：US15749775

申请日：2016-08-02

Applicant: NOVARTIS AG

Inventor： Brian BOETTCHER ,  Shari Lynn CAPLAN ,  Regis CEBE ,  Guochun LI ,  John A TARASZKA ,  Fangmin XU ,  David Langdon YOWE

IPC: C07K16/28 ,  A61P3/00

Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20220162300A1

公开(公告)日：2022-05-26

申请号：US17539335

申请日：2021-12-01

Applicant: Novartis AG

Inventor： Brian BOETTCHER ,  Shari Lynn CAPLAN ,  Regis CEBE ,  Guochun LI ,  John A. TARASZKA ,  Fangmin XU ,  David Langdon YOWE

IPC: C07K16/28 ,  A61P3/00

Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20190100752A1

公开(公告)日：2019-04-04

申请号：US16083327

申请日：2017-03-08

Applicant: Novartis AG

Inventor： Shari Lynn CAPLAN ,  Katsumasa NAKAJIMA

IPC: C12N15/11 ,  C07H21/02 ,  C12N15/87

Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.